Satish Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Promoters of Emcure Pharmaceuticals — Satish Mehta, Sunil Mehta, Samit Mehta, and Namita Thapar — have filed their annual declaration under Regulation 31(4) of the SEBI Takeover Regulations for FY25 (ended March 31, 2025). They confirmed that no encumbrance was created on their equity shares during the year, except for one disclosure: Mrs. Smita Paresh Shah, a member of the promoter group, pledged 60,000 equity shares of the company. The filing includes the full list of 55 persons acting in concert, including promoter group entities, trusts, LLPs, and family members. The declaration was submitted on April 7, 2025, from Pune.
This is a routine annual compliance filing. The pledge of 60,000 shares by one promoter group member is very small relative to the company's total share base, so it is unlikely to materially affect shareholder sentiment or stock price. Investors should note it as a minor encumbrance flag but there is no cause for concern.